U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Apple Turns 50: From Garage Startup to AI Crossroads 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
GAITHERSBURG, Md., Sept. 07, 2016 -- OpGen, Inc. (NASDAQ:OPGN) an informatics and genomic analysis company, announces that Evan Jones, the Company’s Chairman and Chief Executive Officer, will provide a corporate update at the Rodman & Renshaw 18th Annual Global Investment Conference. Mr. Jones’ presentation will be on Monday, September 12, 2016 at 3:25 p.m. Eastern time. The conference is being held from September 11 to 13 in New York City.
To listen to the presentation live, investors may visit the investor relations section of OpGen, Inc.’s website at www.opgen.com. An archived audio of the presentation will also be available on OpGen’s website for 90 days.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
Contacts:
OpGen
Michael Farmer
Director, Marketing
(240) 813-1284
[email protected]
[email protected]
Investor Relations
LHA
Kim Sutton Golodetz
(212) 838-3777
[email protected]
Bruce Voss
(310) 691-7100
[email protected]
OpGen Media
MacDougall Biomedical Communications
Cammy Duong
(781) 235-3060
[email protected]
